Table 3.
Populations included in meta-analysis of the MC1R p.R160W variant in PD.
| Study | population | Number of PD patients, (% carriers of the MC1R p.R160W variant)a |
Number of controls (% carriers of the MC1R p.R160W variant) |
|---|---|---|---|
| Dong et al.13 | Non-Hispanic whites |
777 (13.6%) | 1550 (12.5%) |
| Tell-Marti et al.11 |
Caucasians from Spain |
870 (5.0%) | 736 (2.0%) |
| Current study | Mainly French- Canadian / French |
551 (9.6%) | 956 (7.8%) |
| Current study | North-American from NY |
539 (8.9%) | 265 (9.8%) |
| Current study total |
1090 (9.3%) | 1221 (8.2%) |
a
Since RBD patients may convert to other synucleinopathies, such as Dementia with Lewy Bodies and Multiple System Atrophy, they were not included in the meta-analysis for the effect of the MC1R p.R160W variant on PD risk.